- Home
- ARVN vs DIAX Comparison
ARVN vs DIAX Comparison
Compare ARVN & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- DIAX
- Stock Information
- Founded
- ARVN 2015
- DIAX 2005
- Country
- ARVN United States
- DIAX United States
- Employees
- ARVN N/A
- DIAX N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- DIAX Finance Companies
- Sector
- ARVN Health Care
- DIAX Finance
- Exchange
- ARVN Nasdaq
- DIAX Nasdaq
- Market Cap
- ARVN 456.2M
- DIAX 537.5M
- IPO Year
- ARVN 2018
- DIAX N/A
- Fundamental
- Price
- ARVN $7.61
- DIAX $14.48
- Analyst Decision
- ARVN Buy
- DIAX
- Analyst Count
- ARVN 22
- DIAX 0
- Target Price
- ARVN $20.02
- DIAX N/A
- AVG Volume (30 Days)
- ARVN 1.3M
- DIAX 96.6K
- Earning Date
- ARVN 10-29-2025
- DIAX 01-01-0001
- Dividend Yield
- ARVN N/A
- DIAX 7.93%
- EPS Growth
- ARVN N/A
- DIAX N/A
- EPS
- ARVN N/A
- DIAX N/A
- Revenue
- ARVN $372,800,000.00
- DIAX N/A
- Revenue This Year
- ARVN $1.61
- DIAX N/A
- Revenue Next Year
- ARVN N/A
- DIAX N/A
- P/E Ratio
- ARVN N/A
- DIAX N/A
- Revenue Growth
- ARVN 299.57
- DIAX N/A
- 52 Week Low
- ARVN $5.90
- DIAX $12.80
- 52 Week High
- ARVN $29.61
- DIAX $15.12
- Technical
- Relative Strength Index (RSI)
- ARVN 49.90
- DIAX 44.81
- Support Level
- ARVN $7.58
- DIAX $14.37
- Resistance Level
- ARVN $7.89
- DIAX $14.82
- Average True Range (ATR)
- ARVN 0.37
- DIAX 0.10
- MACD
- ARVN -0.03
- DIAX -0.04
- Stochastic Oscillator
- ARVN 18.42
- DIAX 24.44
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest
Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.